Related references
Note: Only part of the references are listed.T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
Simo Xia et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
Bola S. Hanna et al.
LEUKEMIA (2019)
Ibrutinib enhances the efficacy of ROR1 bispecific T cell engager mediated cytotoxicity in chronic lymphocytic leukaemia
Satyen H. Gohil et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Genetic Deficiency and Biochemical Inhibition of ITK Affect Human Th17, Treg, and Innate Lymphoid Cells
Ahmet Eken et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2019)
The efficacy of anti-CD19 chimeric antigen receptor T cells for B-cell malignancies
Jun-Xia Cao et al.
CYTOTHERAPY (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma
Yi-Xin Zou et al.
HEMATOLOGICAL ONCOLOGY (2019)
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Jan A. Burger et al.
BLOOD (2019)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Sarah E. Josefsson et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
K. Kondo et al.
LEUKEMIA (2018)
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
Hannah R. Robinson et al.
BLOOD (2018)
Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL
Gonzalo Blanco et al.
ONCOIMMUNOLOGY (2018)
Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia
Georg Aue et al.
JOURNAL OF IMMUNOLOGY (2018)
A phase 1 study of lenalidomide and ibrutinib in combination with rituximab in relapsed and refractory CLL
Chaitra Ujjani et al.
BLOOD ADVANCES (2018)
Partial Reconstitution of Humoral and Cellular Immunity in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib
Christopher Pleyer et al.
BLOOD (2018)
Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL
Jordan Gauthier et al.
BLOOD (2018)
Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate
Saar I. Gill et al.
BLOOD (2018)
Ibrutinib Increases the Clonality of TCR Repertoire in Patients with Chronic Lymphocytic Leukemia
Maria Joao Baptista et al.
BLOOD (2018)
Ibrutinib-Based Therapy Improves Anti-Tumor T Cell Killing Function Allowing Effective Pairing with Anti-PD-L1 Immunotherapy Compared to Traditional FCR Chemoimmunotherapy; Implications for Therapy and Correlative Immune Functional Data from the Phase III E1912 Trial
Despoina Papazoglou et al.
BLOOD (2018)
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance)
John C. Byrd et al.
BLOOD ADVANCES (2018)
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu-Monette et al.
BLOOD (2018)
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
Viralkumar Patel et al.
CLINICAL CANCER RESEARCH (2017)
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Marzia Palma et al.
HAEMATOLOGICA (2017)
Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements
A. Vardi et al.
LEUKEMIA (2017)
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Marzia Palma et al.
HAEMATOLOGICA (2017)
Frequency and functional characterization of exhausted CD8+ T cells in chronic lymphocytic leukemia
Saeid Taghiloo et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib
Cameron J. Turtle et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
Qingsong Yin et al.
JOURNAL OF IMMUNOLOGY (2017)
Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number
Monika Podhorecka et al.
ONCOTARGET (2017)
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors
J. Molina-Cerrillo et al.
CANCER TREATMENT REVIEWS (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia
Anna Vardi et al.
CLINICAL CANCER RESEARCH (2016)
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study
Carsten U. Niemann et al.
CLINICAL CANCER RESEARCH (2016)
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
Christine E. Ryan et al.
BLOOD (2016)
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Joseph A. Fraietta et al.
BLOOD (2016)
The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
Marco Ruella et al.
CLINICAL CANCER RESEARCH (2016)
Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
Maria-Elisabeth Goebeler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth
Jun Chen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lenalidomide Maintenance after Front Line Therapy Substantially Prolongs Progression Free Survival in High Risk CLL: Interim Results of a Phase 3 Study (CLL M1 study of the German CLL Study Group)
Anna Maria Fink et al.
BLOOD (2016)
Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma
D. Masso-Valles et al.
CANCER RESEARCH (2015)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia
Adrian Wiestner
HAEMATOLOGICA (2015)
Regulatory T-cell and T-helper 17 balance in chronic lymphocytic leukemia progression and autoimmune cytopenias
Deepesh P. Lad et al.
LEUKEMIA & LYMPHOMA (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival
Z-Z Yang et al.
BLOOD CANCER JOURNAL (2015)
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia
Adrian Wiestner
HAEMATOLOGICA (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Characterization of Bispecific T-cell Engager (BiTE®) Antibodies with a High-Capacity T-cell Dependent Cellular Cytotoxicity (TDCC) Assay
Aaron A. Nazarian et al.
JOURNAL OF BIOMOLECULAR SCREENING (2015)
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Arnon P. Kater et al.
BLOOD (2014)
Itk-mediated integration of T cell receptor and cytokine signaling regulates the balance between Th17 and regulatory T cells
Julio Gomez-Rodriguez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Non-Small Cell Lung Cancer Cells
Wen Gao et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
John C. Riches et al.
BLOOD (2013)
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Jason A. Dubovsky et al.
BLOOD (2013)
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells
Ryan Wong et al.
HAEMATOLOGICA (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Soluble and Membrane-Bound TGF-β-Mediated Regulation of Intratumoral T Cell Differentiation and Function in B-Cell Non-Hodgkin Lymphoma
Zhi-Zhang Yang et al.
PLOS ONE (2013)
Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia
Farhad Jadidi-Niaragh et al.
TUMOR BIOLOGY (2013)
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
Alan G. Ramsay et al.
BLOOD (2012)
Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression
Claudia Nunes et al.
CLINICAL CANCER RESEARCH (2012)
Reciprocal changes in regulatory T cells and Th17 helper cells induced by exercise in patients with chronic lymphocytic leukemia
Chava Perry et al.
LEUKEMIA & LYMPHOMA (2012)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
Davide Bagnara et al.
BLOOD (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
CD39 Expression on T Lymphocytes Correlates With Severity of Disease in Patients With Chronic Lymphocytic Leukemia
Dianne Pulte et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2011)
Origins of CD4+ effector and central memory T cells
Marion Pepper et al.
NATURE IMMUNOLOGY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis
Jean M. Fletcher et al.
JOURNAL OF IMMUNOLOGY (2009)
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug
Alan G. Ramsay et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people
Sven Koch et al.
IMMUNITY & AGEING (2008)
CD4+ CD25+ Foxp3+ regulatory T cells induce cytokine deprivation -mediated apoptosis of effector CD4+ T cells
Pushpa Pandiyan et al.
NATURE IMMUNOLOGY (2007)
Molecular signature of CD8+ T cell exhaustion during chronic viral infection
E. John Wherry et al.
IMMUNITY (2007)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells
G Görgün et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Clonal T-cell populations and increased risk for cytotoxic T-cell lymphomas in B-CLL patients - Clinicopathologic observations and molecular analysis
A Martinez et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia - the three-color flow cytometry analysis
M Podhorecka et al.
LEUKEMIA RESEARCH (2002)
The critical role of Th1-dominant immunity in tumor immunology
T Nishimura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Share Paper
